Zobrazeno 1 - 10
of 197
pro vyhledávání: '"tumor-agnostic"'
Autor:
Karin Holmskov Hansen, Maria Bibi Lyng, Annette Raskov Kodahl, Jon Thor Asmussen, Arman Arshad, Henrik Petersen, Lotte Krogh, Sidse Ehmsen, Thomas Kielsgaard Kristensen, Henrik J. Ditzel
Publikováno v:
BMC Medical Genomics, Vol 17, Iss 1, Pp 1-9 (2024)
Abstract Background Genomic profiling of advanced solid cancer in patients with no further evidence based standard treatment options is a novel approach to identify potential experimental treatment options based on specific genomic alterations. Due t
Externí odkaz:
https://doaj.org/article/18375af606d74035b84b63ee801e359c
Publikováno v:
IJU Case Reports, Vol 6, Iss 6, Pp 382-385 (2023)
Introduction Advanced adrenocortical carcinoma has a poor prognosis and is treated with chemotherapy that includes mitotane with etoposide, doxorubicin, and cisplatin as first‐line therapy. However, second‐line therapy has not been determined yet
Externí odkaz:
https://doaj.org/article/c8bd35fd5ace4291916c35ee0767c5b2
Autor:
Semir Vranic, Zoran Gatalica
Publikováno v:
Biomolecules & Biomedicine (2024)
Oncologic treatment has recently undergone substantial therapeutic paradigm shifts, from classical tumor-specific and biomarker-agnostic approaches to more molecular, biomarker-specific, and tumor-agnostic. Tumor-type (histology) agnostic drugs work
Externí odkaz:
https://doaj.org/article/e3f3a473c5bb43eaa8f371c5848cfc3e
Publikováno v:
Cells, Vol 13, Iss 12, p 1071 (2024)
Cancer accounted for 10 million deaths in 2020, nearly one in every six deaths annually. Despite advancements, the contemporary clinical management of human neoplasms faces a number of challenges. Surgical removal of tumor tissues is often not possib
Externí odkaz:
https://doaj.org/article/683c0799b7544c6d9a51d74ce92089ea
Autor:
Michael J. Dennis, Sophia Bylsma, Lisa Madlensky, Meghana S. Pagadala, Hannah Carter, Sandip P. Patel
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundImpaired DNA damage response (DDR) can affect immune checkpoint inhibitors (ICI) efficacy and lead to heightened immune activation. We assessed the impact of pathogenic or likely pathogenic (P/LP) germline DDR mutations on ICI response and
Externí odkaz:
https://doaj.org/article/1e0413811b3145389253abec7216b286
Autor:
Adetayo Kasim, Nathan Bean, Sarah Jo Hendriksen, Tai-Tsang Chen, Helen Zhou, Matthew A. Psioda
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundBasket trials are increasingly used in oncology drug development for early signal detection, accelerated tumor-agnostic approvals, and prioritization of promising tumor types in selected patients with the same mutation or biomarker. Partici
Externí odkaz:
https://doaj.org/article/19cc1e46da8944bb992070166f6d3f2a
Autor:
Tina Kringelbach, Martin Højgaard, Kristoffer Rohrberg, Iben Spanggaard, Britt Elmedal Laursen, Morten Ladekarl, Charlotte Aaquist Haslund, Laurine Harsløf, Laila Belcaid, Julie Gehl, Lise Søndergaard, Rikke Løvendahl Eefsen, Karin Holmskov Hansen, Annette Raskov Kodahl, Lars Henrik Jensen, Marianne Ingerslev Holt, Trine Heide Oellegaard, Christina Westmose Yde, Lise Barlebo Ahlborn, Ulrik Lassen
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background An increasing number of trials indicate that treatment outcomes in cancer patients with metastatic disease are improved when targeted treatments are matched with druggable genomic alterations in individual patients (pts). An estim
Externí odkaz:
https://doaj.org/article/904750a8228c462b9f8145bcff4832b1
Autor:
Taigo Kato, Nobuaki Matsubara, Masaki Shiota, Masatoshi Eto, Takahiro Osawa, Takashige Abe, Nobuo Shinohara, Yota Yasumizu, Nobuyuki Tanaka, Mototsugu Oya, Koshiro Nishimoto, Takuji Hayashi, Masashi Nakayama, Takahiro Kojima, Kenjiro Namikawa, Takao Fujisawa, Susumu Okano, Eisuke Hida, Yoshiaki Nakamura, Hideaki Bando, Takayuki Yoshino, Norio Nonomura
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-6 (2022)
Abstract Background Previous clinical trials have demonstrated the potential efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) in patients with cancer involving homologous recombination repair (HRR) gene-mutation. Moreover, HRR gene
Externí odkaz:
https://doaj.org/article/5f0dc8735dd54b21bcb309ee64c3e011
Publikováno v:
Journal of Contemporary Medicine, Vol 12, Iss 6, Pp 1019-1024 (2022)
Neurotrophic tyrosine receptor kinase (NTRK) gene rearrangements have been recently identified and developed as one of the biomarkers that have been utilized as new targets for cancer therapy. NTRK gene fusions have taken their place in individualize
Externí odkaz:
https://doaj.org/article/2c2440fcc5bd471885750cdac3cb780e
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.